Clinical Trial Update: An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION) [Phase 2]

View source ↗

Summary

Phase 2 trial update for a biomarker-driven targeted therapy in platinum-resistant recurrent ovarian cancer (AMBITION).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Platinum-resistant Recurrent Ovarian Cancer

Snippet

Sponsor: Yonsei University | Conditions: Platinum-resistant Recurrent Ovarian Cancer | Phase 2 | Status: UNKNOWN